Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behçet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n...

Full description

Saved in:
Bibliographic Details
Published in:British journal of ophthalmology 1992-04, Vol.76 (4), p.241-243
Main Authors: Ozyazgan, Y., Yurdakul, S., Yazici, H., Tüzün, B., Işçimen, A., Tüzün, Y., Aktunç, T., Pazarli, H., Hamuryudan, V., Müftüoğlu, A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Behcet Syndrome - drug therapy
Biological and medical sciences
Cyclophosphamide - administration & dosage
Cyclophosphamide - therapeutic use
Cyclosporine - administration & dosage
Cyclosporine - therapeutic use
Female
Humans
Immunomodulators
Male
Medical sciences
Pharmacology. Drug treatments
Single-Blind Method
Time Factors
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behçet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n = 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n = 11). During the initial 6 months the visual acuity significantly improved (p < 0.001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially long-term studies of cyclosporin A in the uveitis of Behçet's syndrome are warranted.
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.76.4.241